Clinical Trials Browser

Anemia, Aplastic, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Large Granular Lymphocytic

NCT00698685 2017-03-31

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Terminated

14 enrolled 7 charts

GenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Carcinoma, Renal Cell, Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00578903 2016-04-22

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Phase 2 Terminated

22 enrolled 11 charts

Classical hematologyLymphoid

Anemia, Aplastic, Lymphoma, Follicular

NCT01518153 2016-03-17

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Phase 2 Terminated

16 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT00871546 2015-08-07

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Phase 2 Terminated

8 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00771602 2015-06-23

Alemtuzumab + Rituximab Consolidation in CLL

Phase 2 Terminated

1 enrolled 2 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00262925 2015-05-05

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2 Terminated

12 enrolled 6 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00781781 2015-02-04

Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning

Phase 2 Terminated

34 enrolled

Graft vs Host Disease

NCT00818961 2013-12-18

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Phase 2 Terminated

36 enrolled 16 charts

LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT00069992 2012-10-10

MPDMDSBMT

Phase 2 Terminated

7 enrolled

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT00453193 2012-08-07

Alemtuzumab and Pentostatin In T-cell Neoplasms

Phase 2 Terminated

26 enrolled 5 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT00505921 2011-11-16

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Phase 2 Terminated

27 enrolled 5 charts

Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT00441025 2009-06-25

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Phase 2 Terminated

4 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

Clinical Trials

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Cyclosporine Plus Methotrexate or Alemtuzumab

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Alemtuzumab + Rituximab Consolidation in CLL

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

MPDMDSBMT

Alemtuzumab and Pentostatin In T-cell Neoplasms

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL